ALISO VIEJO, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) — RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming J.P. Morgan Healthcare Conference.
RxSight’s management is scheduled to present on Tuesday, January 13, 2026, at 3:45 p.m. Pacific Time / 6:45 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation at: https://investors.rxsight.com/.
About RxSight, Inc.
RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The RxSight® Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens® (LAL®/LAL+®, collectively the “LAL”), RxSight Light Delivery Device (LDD™) and accessories, is the first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery, enabling doctors to customize and deliver high-quality vision to patients after cataract surgery. Additional information about RxSight can be found at www.rxsight.com.
Company Contact:
Shelley B. Thunen
Chief Financial Officer
sthunen@rxsight.com
Investor Relations Contact:
Oliver Moravcevic
VP, Investor Relations
omoravcevic@rxsight.com


Đề xuất
MagnesiumFreeze Sciatic Nerve Claims Evaluated: Consumer Research Report Examines Magnesium Niacinamide Relief Topical Cream Ingredients, NAD+ Science, and Sciatic Nerve Support Discussions
AIM ImmunoTech Announces Closing of its Rights Offering
Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc.
Curaechoice and Health Benefit Alliance Partner to Deliver No-Cost Healthcare to 161,000 Members Across 42 States
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Autoliv announces appointment of new CFO